Navigating the healthcare system and its processes can seem overwhelming to patients. If patients understand why their clinician recommended something, know how and when to take medications, and why they shouldn’t skip a dose—or 10—they may not feel so out of control. Sharing examination notes with patients can be helpful to many patients who struggle…
Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…
Camelot allegedly existed once upon a time in South Wales. The name was evoked again in the 1960s, but perhaps it is also applicable to the character of rheumatology in the halcyon days of the 1970s and 80s. That’s not to belittle the world we now live in, with so many treatment options for our…
Experts discussed the heavy toll the pandemic has taken on patients and clinicians, with many patients in need of mental health support and others in need of rehabilitation.
Rheumatology has arguably benefited like no other field from the proliferation of an increasingly effective pipeline of therapeutics. These medications have dramatically raised the bar for clinical outcomes for our patients in a way that we could not have envisioned a short generation ago. With such therapeutic progress now reaching a widening circle of rheumatic…
It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…
As the new chair of the Registries & Health Information Technology Committee, William F. Harvey, MD, MSc, hopes to expand representation of patient diversity in the RISE registry and increase the use of registry data for research.
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.